| IN TR ODUC TION
Surgical shunt attenuation is the treatment of choice in dogs with congenital portosystemic shunt (CPSS) to restore the normal hepatoportal circulation and liver function. 1 Recovery from portosystemic shunting after attenuation of the shunt in an individual dog is unpredictable and complications after shunt attenuation such as portal hypertension, persistence or recurrence of clinical signs because of continuous shunting or development of collaterals have been described for all surgical techniques. 2 Overall mortality rates differ from 0% to 32% depending on surgical technique, shunt localization, and extent of narrowing. [2] [3] [4] Long-term medical management to control clinical signs associated with CPSS, particularly hepatic encephalopathy, is considerably less effective than surgery. It is only recommended in cases with predicted poor surgical outcome. 5, 6 Therefore, an accurate preoperative model for predicting the outcome of shunt attenuation is essential.
It is unclear which factors contribute to success or failure after surgical treatment, making the prediction of long-term outcome after surgical attenuation of CPSS difficult. Predictors associated with recovery after surgical attenuation are age at surgery, 7, 8 weight, preoperative plasma protein and albumin concentrations, blood urea nitrogen concentration, 7 shunt localization, 9 and leukocyte count, 4 although results are inconsistent. Intraoperative mesenteric portovenography can be helpful to predict outcome after surgical treatment of a single CPSS, 8 although this technique currently is solely useful intraoperatively.
An essential factor affecting postoperative recovery after surgery is hepatic regenerative capacity (ie, the ability of the liver and portal vasculature to develop to normal size and function). 3, 10 Hepatic regeneration is promoted by a complex network activated by inflammatory cytokines, vasoregulators, growth factors, eicosanoids, and various hormones 11 and correlates with hepatic expression of genes involved in proliferation, apoptosis, hepatic fibrosis and vascular growth. 12 A positive association with complete recovery after shunt attenuation was found for 2 genes related to hepatocyte proliferation: HGF activator (HGFact) and methionine adenosyltransferase 2a (MAT2a), 12 suggesting that expression of these genes after surgery is important for clinical recovery. 12, 13 These 2 and other factors have been evaluated extensively, 3, 4, [12] [13] [14] but no model based on genome-wide gene expression studies is available yet to predict recovery from portosystemic shunting after surgical attenuation of CPSS. Our aim was to develop an algorithm that predicts the outcome of surgery, in terms of normalization of portal circulation and restoration of ammonia metabolism. Therefore, a canine specific gene expression study was performed in intraoperatively obtained hepatic tissue of dogs with CPSS. Expression profiles were compared between dogs with recovery and dogs without recovery from portosystemic shunting upon surgical attenuation of the shunt. The results were used to construct a prediction model for postoperative recovery in these dogs.
| M A TER I A L A N D M ETH OD S

| Study design
Gene expression profiles were generated from dogs with CPSS that underwent surgical attenuation of the shunt in 2 case-control studies where cases recovered after surgery and controls did not. In the 1st study, genes that were associated with successful recovery upon surgical attenuation were selected by microarray analysis. In the 2nd study, the association with recovery of these genes was confirmed by quantitative real-time PCR (RT-qPCR). The genes selected from the 2nd study and variables such as the hepatic mRNA expression of MAT2a and HGFact, plasma albumin concentration, 7, 12 sex, age at surgery, 7, 8 breed, and shunt localization 9 that are reported to possibly be related with recovery, were used to create a prediction model for recovery after surgery.
| Surgical procedure
Data of 73 dogs referred to the Department of Clinical Sciences of
Companion Animals, Utrecht University for surgical attenuation of a single CPSS were included in the study. Permission was obtained from the dog owners using informed consent. The location of the shunt (intrahepatic or extrahepatic) was preoperatively determined using ultrasonography or computed tomography (CT). Additional preoperative and postoperative diagnostic tests, supportive treatment, and monitoring were performed according to a standardized CPSS protocol, which included preoperative plasma albumin concentrations measured using a DxC 600 Beckman analyzer (Beckman Coulter, Woerden, The Netherlands). After exploration of the abdominal cavity via median celiotomy, the shunt was ligated over a gauged rod to the smallest diameter that did not induce portal hypertension, using a non- 
| Surgical outcome
shunting was evaluated by a 12-hour fasting plasma ammonia concentration or by performing a rectal ammonia tolerance test. 15 Abdominal ultrasonography was performed to examine the site and patency of the attenuated shunt and to identify acquired portosystemic vessels. study to ensure that only robust changes were considered.
In the 2nd study, liver tissue from 62 samples (31 recovered, 31 nonrecovered dogs) was analyzed. Gene expression differences of the selected genes were confirmed using RT-qPCR. RNA isolation, cDNA synthesis, and gene expression profiling using RT-qPCR was performed as described previously 16 with a maximum of 40 cycles. 
| Statistical analysis
For the 1st study, the results of the microarray analysis were reanalyzed with updated annotations using analysis of variance (ANOVA) 18 using R statistics (R version 2.2.1, R Foundation for Statistical Computing, Vienna, Austria). Correction for multiple testing (Permutation F2-test using 5000 permutations) was performed and P < .05 after familywise error correction was considered statistically significant. 
Abbreviations: CAV2, caveolin-2; CPD, carboxypeptidase D precursor; CTGF, connective tissue growth factor precursor; CYR61, protein CYR61 precursor (IGFbinding protein 10); DHDH, dimeric dihydrodiol dehydrogenase; DZIP, zinc finger protein DZIP1 (DAZ-interacting protein 1/2); ERLEC1, endoplasmic reticulum lectin 1; FRMD4B, FXYD1, GLS2, glutaminase liver isoform, mitochondrial precursor; GNMT, glycine N-methyltransferase; GSTO1, glutathione transferase omega-1; HEPC, hepcidin precursor; HGFA, hepatocyte growth factor activator; HSD17B14, 17-beta-hydroxysteroid dehydrogenase 14; LYSMD2, LysM and putative peptidoglycan-binding domain-containing protein 2; MAT2a, methionine adenosyltransferase 2 alpha; MFAP3, microfibrillar-associated protein 3-like precursor; MGST2, microsomal glutathione S-transferase 2; NAGS, N-acetylglutamate synthase, mitochondrial precursor; NUCB2, nucleobindin-2 precursor; PDIA4, protein disulfide-isomerase A4 precursor; PIK3RA, phosphatidylinositol 3-kinase regulatory subunit alpha; PKIB, cAMP-dependent protein kinase inhibitor beta; PLIN2, Adipophilin; SEH1L, SEH1 Like Nucleoporin; SK2, small conductance calcium-activated potassium channel protein 2; SLC1A1, solute carrier family 1 (glial high affinity glutamate transporter), member 1; SLC2A13, solute carrier family 2 (facilitated glucose transporter), member 13; SORD, sorbitol dehydrogenase; SSH3L, protein phosphatase Slingshot homolog 3; TFAP2B, transcription factor AP-2 beta; TOR3A, Torsin-3A precursor; TRIM22, tripartite motif-containing protein 22; TXNIP, thioredoxin-interacting protein; VCAM1, vascular cell adhesion molecule 1. Reference genes used for normalization: GUSB, glucuronidase beta; hnRPH, heterogeneous nuclear ribonucleoprotein H; HPRT, hypoxanthine phosphoribosyl transferase; RPS5, ribosomal protein S5; F, forward primer; R, reverse primer; T m , melting temperature; bp, base pairs.
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| Gene expression patterns of recovered and nonrecovered dogs
In the microarray data set, 43 genes were differentially expressed in recovered and non-recovered CPSS dogs. 16 These genes were selected for further confirmation by RT-qPCR. RT-qPCR was technically not possible in 9 genes (CYP2d15, FBLIM1, GLYCK, HMT, IGHV, LIPH, MMD, RBP3, and TCEA3). Therefore, qPCR was performed on 36 genes, including MAT2a and HGFact (Table 1) . Because of technical reasons, no RT-qPCR data could be obtained for 3 genes: CYR61, MGST2, and SEH1L.
| Construction of the prediction model
The ROC curves of albumin and the DCqs of CTGF, DHDH, ERLEC1, HEPC, LYSMD2, ZIP had AUCs that were significantly (P < .05) different from 0.5. The final logistic model included binary variables for albumin, DHDH, ERLEC1, and LYSMD2 (Table 3 ). The AUC was 0.887 (95% RT-qPCR study (in both studies) EHPSS 14 (6) 21 (16) 35 (22) IHPSS 17 (9) 10 (4) 27 (13) Total 31 (15) 31 (20) 62 (35) Abbreviations: EHPSS, extrahepatic portosystemic shunt; IHPSS, intrahepatic portosystemic shunt. in which p is the predicted probability of recovery.
With this adapted model, recovery of new individual dogs can be predicted using preoperative plasma albumin concentration and the hepatic mRNA expression of the 3 genes of interest as a binary variable ("0" or "1"; Table 4 ).
| D ISCUSSION
A prediction model was composed based on the expression levels of Our study confirmed the association of low plasma albumin concentrations with poor recovery, as described before. 4, 7, 12 Albumin is synthesized exclusively by hepatocytes. In dogs with portosystemic shunts, hypoalbuminemia is common and could be related to prolonged hepatocellular dysfunction. Although plasma albumin concentration is The double line indicates the threshold of surgery at a probability of recovery > 50%. Abbreviations: p, probability of recovery; R, number of recovered dogs; NR, number of nonrecovered dogs.
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Journal of Veterinary Internal Medicine Previously, we found a positive association between complete recovery after shunt attenuation and plasma albumin concentrations as well as MAT2a and HGFact expression, 2 genes selected on potential prognostic value to recovery (involvement in hepatic regeneration and vascular growth, respectively). 12 In contrast to the previous study, the present study included more dogs and used a genome-wide microarray expression approach to objectively select genes of interest, and selection was not based on known gene function or pathway. Although
MAT2a and HGFact were added as potential predictors in the construction of the model and these genes are important in liver cell proliferation, 12, 13 neither of the 2 genes significantly contributed to the final model in our study.
A correlation between shunt localization, weight, age at time of surgery, and clinical outcome is suggested in several studies. Because severe shunting leads to poor liver development and function, 23 it seems plausible that dogs with a higher fraction of shunted portal flow develop clinical signs at an earlier age. Hence, a negative correlation of age to recovery could be expected and explained by poor clinical condition of such dogs. In contrast, better prognosis was reported after surgical treatment in dogs < 12 months of age, compared with dogs >2 years. 24 In our population, no correlation between age at surgery and recovery has been detected, which also has been found by others. 1, 25 Because IHPSS occurs more often in large dog breeds and EHPSS in small dog breeds, 26 shunt localization, and weight are expected to be correlated when investigating factors associated with recovery rates. Although plausible, shunt localization did not contribute to the final prediction model.
Recovery was defined as normalization of plasma ammonia metabolism and no portosystemic shunting on abdominal ultrasonography.
Although fasted bile acid concentrations often are more easy to measure and are very sensitive in screening dogs for CPSS, preprandial and postprandial serum bile acid concentrations also are reported to remain increased after complete ligation of CPSS in the majority of dogs, also in dogs without evidence of portosystemic shunting on ultrasonography. Measurement of fasting blood ammonia concentration is therefore the testing method of choice for diagnosing portosystemic shunting after surgery. An additional ammonia tolerance test or ultrasonography could rule out portosystemic shunting completely. 15, 27 Although also a reliable technique, shunt fractions, using scintigraphy, were not measured in our study because of invasiveness and cost. By not consid- Hepatic gene expression profiles and recovery rates after attenuation of a shunt are probably not identical among various countries because of population and individual breed differences. 21 Differences in preoperative medical treatment of dogs also may influence hepatic metabolism and gene expression. Although management with a lowprotein diet is routinely instituted in our dogs before surgery, additional medication is not standardized and differs among clinics. Moreover, the various surgical regimens for shunt attenuation and variations in surgical skills also affect outcome. Preferably, surgical techniques and skills, but also perioperative monitoring and treatment, should be optimized and standardized. Although surgeon was not predictive in our study (data not shown), this is not a variable that we wanted to include in a model that would be widely applicable. An international multicenter study to validate this model is essential for it to become applicable world-wide. However, the best performance is to be expected from a model that is validated under the same conditions as will be used in new cases.
To obtain reliable predictions provided by a clinical prediction model, at least 10 events per predictor is advised. 29 Based on the previous study, 12 at least 30 samples per event (recovery and nonrecovery) were included in the 2nd part of this study. However, the number of dogs in relation to the number of predictors that eventually were used to construct the final model is small and is a limitation of our study. Therefore, more samples will be needed when validating this model.
In conclusion, a preclinical prediction model was constructed based on plasma albumin concentration and hepatic expression of 3 genes (DHDH, ERLEC1, and LYSMD2) as binary variables. This model had good discriminating ability to predict resolution of portosystemic shunting at 1 to 3 months after shunt attenuation by ligation in dogs. External validation of this model in other dog populations and using different surgical (preoperative) liver biopsy and analyzing techniques is essential to evaluate the broad clinical applicability of the model. Development of less invasive ways to measure predictive gene expression, for example using peripheral venous blood samples, is important to increase practical applicability.
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